Retrospective Analysis of the Treatment Outcome in Myeloid Leukemia of Down Syndrome in Polish Pediatric Leukemia and Lymphoma Study Group From 2005 to 2019

Children with Down syndrome (DS) have increased risk of myeloid leukemia (ML), but specific treatment protocols ensure excellent outcome. This study was a retrospective analysis of the treatment results and genetic characteristics of ML of DS (ML-DS) in Poland from 2005 to 2019. All 54 patients with ML-DS registered in the Polish Pediatric Leukemia and Lymphoma Study Group in analyzed period were enrolled to the study. There were 34 children treated with Acute Myeloid Leukemia-Berlin-Frankfurt-Munster 2004 Interim Protocol (group I) and 20 patients treated with ML-DS 2006 Protocol (group II). In the first protocol, there was reduction of the antracyclines doses and intrathecal treatment for ML-DS compared to non-DS patients. In the second protocol, further reduction of the treatment was introduced (omission of etoposide in the last cycle, no maintenance therapy). Probabilities of 5-year overall survival (OS), event-free survival (EFS), and relapse-free survival in the whole analyzed group were 0.85 ± 0.05, 0.83 ± 0.05, and 0.97 ± 0.03, respectively. No significant differences were found between two protocols in the terms of OS and EFS (0.79 ± 0.07 vs. 0.95 ± 0.05, = 0.14, and 0.76 ± 0.07 vs. 0.95 ± 0.05, = 0.12, respectively). All deaths were caused by the treatment-related toxicities. Reduction of the treatment-related mortality was noticed (20% in group I and 5% in group II). The only one relapse in the whole cohort occurred in the patient from group I, older than 4 years, without gene mutation. He was treated successfully with IdaFLA cycle followed by hematopoietic stem cell transplantation from matched sibling donor. No significant prognostic factor was found in the study group probably due to low number of patients in the subgroups. The study confirms that the reduced intensity protocols are very effective in ML-DS patients. The only cause of deaths was toxicities; however, systematic decrease of the treatment-related mortality was noticed.

Citing Articles

Clonal Myeloproliferative Disorders in Patients with Down Syndrome-Treatment and Outcome Results from an Institution in Argentina.

Pennella C, Cassina T, Rossi J, Baialardo E, Rubio P, Deu M Cancers (Basel). 2022; 14(13).

PMID: 35805057 PMC: 9265690. DOI: 10.3390/cancers14133286.

Acute leukaemia in children with Down syndrome in a low middle-income country.

Ul-Ain R, Faizan M, Anwar S, Riaz S, Ahmad A, Zafar H Ecancermedicalscience. 2022; 16:1374.

PMID: 35702410 PMC: 9116992. DOI: 10.3332/ecancer.2022.1374.

References

Zipursky A, Thorner P, de Harven E, Christensen H, Doyle J . Myelodysplasia and acute megakaryoblastic leukemia in Down's syndrome. Leuk Res. 1994; 18(3):163-71. DOI: 10.1016/0145-2126(94)90111-2. View

Creutzig U, Reinhardt D, Diekamp S, Dworzak M, Stary J, Zimmermann M . AML patients with Down syndrome have a high cure rate with AML-BFM therapy with reduced dose intensity. Leukemia. 2005; 19(8):1355-60. DOI: 10.1038/sj.leu.2403814. View

Langebrake C, Creutzig U, Reinhardt D . Immunophenotype of Down syndrome acute myeloid leukemia and transient myeloproliferative disease differs significantly from other diseases with morphologically identical or similar blasts. Klin Padiatr. 2005; 217(3):126-34. DOI: 10.1055/s-2005-836510. View

Rainis L, Bercovich D, Strehl S, Teigler-Schlegel A, Stark B, Trka J . Mutations in exon 2 of GATA1 are early events in megakaryocytic malignancies associated with trisomy 21. Blood. 2003; 102(3):981-6. DOI: 10.1182/blood-2002-11-3599. View

Taub J, Matherly L, Stout M, Buck S, Gurney J, Ravindranath Y . Enhanced metabolism of 1-beta-D-arabinofuranosylcytosine in Down syndrome cells: a contributing factor to the superior event free survival of Down syndrome children with acute myeloid leukemia. Blood. 1996; 87(8):3395-403. View

Creutzig U, van den Heuvel-Eibrink M, Gibson B, Dworzak M, Adachi S, De Bont E . Diagnosis and management of acute myeloid leukemia in children and adolescents: recommendations from an international expert panel. Blood. 2012; 120(16):3187-205. DOI: 10.1182/blood-2012-03-362608. View

Klusmann J, Creutzig U, Zimmermann M, Dworzak M, Jorch N, Langebrake C . Treatment and prognostic impact of transient leukemia in neonates with Down syndrome. Blood. 2008; 111(6):2991-8. PMC: 2265448. DOI: 10.1182/blood-2007-10-118810. View

Roberts I, Alford K, Hall G, Juban G, Richmond H, Norton A . GATA1-mutant clones are frequent and often unsuspected in babies with Down syndrome: identification of a population at risk of leukemia. Blood. 2013; 122(24):3908-17. PMC: 3995281. DOI: 10.1182/blood-2013-07-515148. View

Labuhn M, Perkins K, Matzk S, Varghese L, Garnett C, Papaemmanuil E . Mechanisms of Progression of Myeloid Preleukemia to Transformed Myeloid Leukemia in Children with Down Syndrome. Cancer Cell. 2019; 36(2):123-138.e10. PMC: 6863161. DOI: 10.1016/j.ccell.2019.06.007. View

10.

Uffmann M, Rasche M, Zimmermann M, von Neuhoff C, Creutzig U, Dworzak M . Therapy reduction in patients with Down syndrome and myeloid leukemia: the international ML-DS 2006 trial. Blood. 2017; 129(25):3314-3321. DOI: 10.1182/blood-2017-01-765057. View

11.

Arber D, Orazi A, Hasserjian R, Thiele J, Borowitz M, Le Beau M . The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016; 127(20):2391-405. DOI: 10.1182/blood-2016-03-643544. View

12.

Blink M, Zimmermann M, von Neuhoff C, Reinhardt D, de Haas V, Hasle H . Normal karyotype is a poor prognostic factor in myeloid leukemia of Down syndrome: a retrospective, international study. Haematologica. 2013; 99(2):299-307. PMC: 3912960. DOI: 10.3324/haematol.2013.089425. View

13.

Vardiman J, Thiele J, Arber D, Brunning R, Borowitz M, Porwit A . The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009; 114(5):937-51. DOI: 10.1182/blood-2009-03-209262. View

14.

Wechsler J, Greene M, McDevitt M, Anastasi J, Karp J, Le Beau M . Acquired mutations in GATA1 in the megakaryoblastic leukemia of Down syndrome. Nat Genet. 2002; 32(1):148-52. DOI: 10.1038/ng955. View

15.

Taga T, Watanabe T, Tomizawa D, Kudo K, Terui K, Moritake H . Preserved High Probability of Overall Survival with Significant Reduction of Chemotherapy for Myeloid Leukemia in Down Syndrome: A Nationwide Prospective Study in Japan. Pediatr Blood Cancer. 2015; 63(2):248-54. DOI: 10.1002/pbc.25789. View

16.

Forestier E, Izraeli S, Beverloo B, Haas O, Pession A, Michalova K . Cytogenetic features of acute lymphoblastic and myeloid leukemias in pediatric patients with Down syndrome: an iBFM-SG study. Blood. 2007; 111(3):1575-83. DOI: 10.1182/blood-2007-09-114231. View

17.

Hasle H . Pattern of malignant disorders in individuals with Down's syndrome. Lancet Oncol. 2002; 2(7):429-36. DOI: 10.1016/S1470-2045(00)00435-6. View

18.

Alford K, Reinhardt K, Garnett C, Norton A, Bohmer K, von Neuhoff C . Analysis of GATA1 mutations in Down syndrome transient myeloproliferative disorder and myeloid leukemia. Blood. 2011; 118(8):2222-38. DOI: 10.1182/blood-2011-03-342774. View

19.

Taub J, Berman J, Hitzler J, Sorrell A, Lacayo N, Mast K . Improved outcomes for myeloid leukemia of Down syndrome: a report from the Children's Oncology Group AAML0431 trial. Blood. 2017; 129(25):3304-3313. PMC: 5482102. DOI: 10.1182/blood-2017-01-764324. View

20.

Hassler A, Bochennek K, Gilfert J, Perner C, Schoning S, Creutzig U . Infectious Complications in Children With Acute Myeloid Leukemia and Down Syndrome: Analysis of the Prospective Multicenter Trial AML-BFM 2004. Pediatr Blood Cancer. 2016; 63(6):1070-4. DOI: 10.1002/pbc.25917. View